Emerging Modern Therapeutic Options in Amyotrophic Lateral Sclerosis (ALS)
DOI:
https://doi.org/10.12775/QS.2026.68.74251Keywords
ALS, emerging therapies in amyotrophic llateral sclerosisAbstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by a rapidly progressive clinical course, ultimately leading to complete paralysis and a profound deterioration of physical and cognitive well-being. For decades, riluzole remained the sole approved therapeutic option. The pharmacological landscape has recently experienced significant revolution. While a definitive cure remains elusive, recent advancements have introduced novel, targeted agents into clinical practice, marking a critical milestone in ALS management. This review presents recent findings and emerging trends in ALS pharmacotherapy. Furthermore, it examines the complex pathophysiology of this multidimensional disease, highlighting the intrinsic biological challenges that complicate the development of universally effective, disease-modifying treatments.
References
[1] Xu, L., Liu, T., Liu, L., Yao, X., Chen, L., Fan, D., Zhan, S., & Wang, S. (2020). Global variation in prevalence and incidence of amyotrophic lateral sclerosis: A systematic review and meta-analysis. Journal of Neurology, 267(4), 944–953. https://doi.org/10.1007/s00415-019-09652-y
[2] Vasta, R., De Mattei, F., Tafaro, S., Canosa, A., Manera, U., Grassano, M., Palumbo, F., Cabras, S., Matteoni, E., Di Pede, F., Zocco, G., Pellegrino, G., Minerva, E., Pascariu, D., Iazzolino, B., Callegaro, S., Fuda, G., Salamone, P., De Marchi, F., … Chiò, A. (2025). Changes to Average Survival of Patients With Amyotrophic Lateral Sclerosis (1995-2018): Results From the Piemonte and Valle d’Aosta Registry. Neurology, 104(8), e213467. https://doi.org/10.1212/WNL.0000000000213467
[3] Masrori, P., & Van Damme, P. (2020). Amyotrophic lateral sclerosis: A clinical review. European Journal of Neurology, 27(10), 1918–1929. https://doi.org/10.1111/ene.14393
[4] Phukan, J., Elamin, M., Bede, P., Jordan, N., Gallagher, L., Byrne, S., Lynch, C., Pender, N., & Hardiman, O. (2012). The syndrome of cognitive impairment in amyotrophic lateral sclerosis: A population-based study. Journal of Neurology, Neurosurgery & Psychiatry, 83(1), 102–108. https://doi.org/10.1136/jnnp-2011-300188
[5] Raoufinia, R., Alyari, G., nia, A. T., Abbaszadegan, M. R., Mahmoudi, A., Shafaeibajestan, S., Saburi, E., Tavakol-Afshari, J., Hassani, M., Jamali, F., Salari, S., Boroumand, A. R., & Rahimi, H. reza. (2025). Cutting-edge treatments in amyotrophic lateral sclerosis: The role of molecular pathogenesis in targeted therapies. Stem Cell Research & Therapy, 16, 689. https://doi.org/10.1186/s13287-025-04781-w
[6] Larson, T. C., Goutman, S. A., Davis, B., Bove, F. J., Thakur, N., & Mehta, P. (2023). Causes of death among United States decedents with ALS: An eye toward delaying mortality. Annals of Clinical and Translational Neurology, 10(5), 757–764. https://doi.org/10.1002/acn3.51762
[7] Goutman, S. A., Hardiman, O., Al-Chalabi, A., Chió, A., Savelieff, M. G., Kiernan, M. C., & Feldman, E. L. (2022). Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. The Lancet. Neurology, 21(5), 465–479. https://doi.org/10.1016/S1474-4422(21)00414-2
[8] Ilieva, H., Vullaganti, M., & Kwan, J. (2023). Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis. The BMJ, 383, e075037. https://doi.org/10.1136/bmj-2023-075037
[9] Al-Khayri, J. M., Ravindran, M., Banadka, A., Vandana, C. D., Priya, K., Nagella, P., & Kukkemane, K. (2024). Amyotrophic Lateral Sclerosis: Insights and New Prospects in Disease Pathophysiology, Biomarkers and Therapies. Pharmaceuticals, 17(10), 1391. https://doi.org/10.3390/ph17101391
[10] Wang, Z., Huang, J., & Yun, D. (2026). Current and emerging therapeutic strategies for amyotrophic lateral sclerosis: From pharmacological approaches to gene and stem cell therapies. Frontiers in Neurology, 17, 1729302. https://doi.org/10.3389/fneur.2026.1729302 [11] Feldman, E. L., Goutman, S. A., Petri, S., Mazzini, L., Savelieff, M. G., Shaw, P. J., & Sobue, G. (2022). Amyotrophic lateral sclerosis. The Lancet, 400(10360), 1363–1380. https://doi.org/10.1016/S0140-6736(22)01272-7
[12] Zou, Z.-Y., Zhou, Z.-R., Che, C.-H., Liu, C.-Y., He, R.-L., & Huang, H.-P. (2017). Genetic epidemiology of amyotrophic lateral sclerosis: A systematic review and meta-analysis. Journal of Neurology, Neurosurgery, and Psychiatry, 88(7), 540–549. https://doi.org/10.1136/jnnp-2016-315018
[13] King, A. E., Woodhouse, A., Kirkcaldie, M. T. K., & Vickers, J. C. (2016). Excitotoxicity in ALS: Overstimulation, or overreaction? Experimental Neurology, 275, 162–171. https://doi.org/10.1016/j.expneurol.2015.09.019
[14] Hollingworth, D., Thomas, F., Page, D. A., Fouda, M. A., De Castro, R. L.-R., Sula, A., Mykhaylyk, V. B., Kelly, G., Ulmschneider, M. B., Ruben, P. C., & Wallace, B. A. (2024). Structural basis for the rescue of hyperexcitable cells by the amyotrophic lateral sclerosis drug Riluzole. Nature Communications, 15(1), 8426. https://doi.org/10.1038/s41467-024-52539-4
[15] Vucic, S., Lin, C. S.-Y., Cheah, B. C., Murray, J., Menon, P., Krishnan, A. V., & Kiernan, M. C. (2013). Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain: A Journal of Neurology, 136(Pt 5), 1361–1370. https://doi.org/10.1093/brain/awt085
[16] Miller, R. G., Mitchell, J. D., & Moore, D. H. (2012). Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). The Cochrane Database of Systematic Reviews, 2012(3), CD001447. https://doi.org/10.1002/14651858.CD001447.pub3
[17] Jiang, J., Li, X., Mi, Y., Wang, Y., Heng, Y., Li, Z., & Deng, M. (2025). Real-world evidence of riluzole on survival and ALSFRS change in a Chinese ALS cohort. Neurodegenerative Disease Management, 15(2–3), 77–87. https://doi.org/10.1080/17582024.2025.2488235
[18] Writing Group & Edaravone (MCI-186) ALS 19 Study Group. (2017a). Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. The Lancet. Neurology, 16(7), 505–512. https://doi.org/10.1016/S1474-4422(17)30115-1
[19] Singh, P., Belliveau, P., Towle, J., Neculau, A. E., & Dima, L. (2024). Edaravone Oral Suspension: A Neuroprotective Agent to Treat Amyotrophic Lateral Sclerosis. American Journal of Therapeutics, 31(3), e258–e267. https://doi.org/10.1097/MJT.0000000000001742
[20] Dakroub, F., Awada, B., Abdelhady, S., Shaito, A. A., Eid, A. H., Walker, J., Mondello, S., Bondi, C. O., Moro, F., Elgendy, B., Wang, K. K., Zanier, E. R., Mechref, Y., & Kobeissy, F. (2026). Edaravone: Advances on cytoprotective effects, pharmacological properties, and mechanisms of action. Pharmacological Reviews, 78(1), 100101. https://doi.org/10.1016/j.pharmr.2025.100101
[21] Mikuriya, S., Takegawa-Araki, T., & Tamura, M. (2025). Edaravone mitigates TDP-43 mislocalization in human amyotrophic lateral sclerosis neurons with potential implication of the SIRT1-XBP1 pathway. Free Radical Biology & Medicine, 230, 283–293. https://doi.org/10.1016/j.freeradbiomed.2025.01.012
[22] Sawada, H. (2017). Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Expert Opinion on Pharmacotherapy, 18(7), 735–738. https://doi.org/10.1080/14656566.2017.1319937
[23] Writing Group & Edaravone (MCI-186) ALS 19 Study Group. (2017b). Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. The Lancet. Neurology, 16(7), 505–512. https://doi.org/10.1016/S1474-4422(17)30115-1
[24] Takei, K., Watanabe, K., Yuki, S., Akimoto, M., Sakata, T., & Palumbo, J. (2017). Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, 18(sup1), 5–10. https://doi.org/10.1080/21678421.2017.1353101
[25] McGuigan, A., & Blair, H. A. (2025). Tofersen: A Review in Amyotrophic Lateral Sclerosis Associated with SOD1 Mutations. CNS Drugs, 39(9), 903–912. https://doi.org/10.1007/s40263-025-01204-5
[26] Miller, T., Cudkowicz, M., Shaw, P. J., Andersen, P. M., Atassi, N., Bucelli, R. C., Genge, A., Glass, J., Ladha, S., Ludolph, A. L., Maragakis, N. J., McDermott, C. J., Pestronk, A., Ravits, J., Salachas, F., Trudell, R., Damme, P. V., Zinman, L., Bennett, C. F., … Ferguson, T. A. (2020). Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 383(2), 109–119. https://doi.org/10.1056/NEJMoa2003715
[27] Blair, H. A. (2023). Tofersen: First Approval. Drugs, 83(11), 1039–1043. https://doi.org/10.1007/s40265-023-01904-6
[28] Brown, C. A., Lally, C., Kupelian, V., & Flanders, W. D. (2021). Estimated Prevalence and Incidence of Amyotrophic Lateral Sclerosis and SOD1 and C9orf72 Genetic Variants. Neuroepidemiology, 55(5), 342–353. https://doi.org/10.1159/000516752
[29] Benatar, M., Robertson, J., & Andersen, P. M. (2025). Amyotrophic lateral sclerosis caused by SOD1 variants: From genetic discovery to disease prevention. The Lancet. Neurology, 24(1), 77–86. https://doi.org/10.1016/S1474-4422(24)00479-4
[30] Miller, T. M., Cudkowicz, M. E., Genge, A., Shaw, P. J., Sobue, G., Bucelli, R. C., Chiò, A., Damme, P. V., Ludolph, A. C., Glass, J. D., Andrews, J. A., Babu, S., Benatar, M., McDermott, C. J., Cochrane, T., Chary, S., Chew, S., Zhu, H., Wu, F., … Fradette, S. (2022). Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 387(12), 1099–1110. https://doi.org/10.1056/NEJMoa2204705
[31] Lovett, A., Chary, S., Babu, S., Bruneteau, G., Glass, J. D., Karlsborg, M., Ladha, S., Mayl, K., McDermott, C., Bucelli, R. C., Chiò, A., Ferguson, T. A., Cochrane, T., Fradette, S., Smirnakis, K., Inra, J., Malek, S., & Fanning, L. (2025). Serious Neurologic Adverse Events in Tofersen Clinical Trials for Amyotrophic Lateral Sclerosis. Muscle & Nerve, 71(6), 1006–1015. https://doi.org/10.1002/mus.28372
[32] Alqallaf, A., Cates, D. W., Render, K. P., & Patel, K. A. (2024). Sodium Phenylbutyrate and Taurursodiol: A New Therapeutic Option for the Treatment of Amyotrophic Lateral Sclerosis. The Annals of Pharmacotherapy, 58(2), 165–173. https://doi.org/10.1177/10600280231172802
[33] Paganoni, S., Macklin, E. A., Hendrix, S., Berry, J. D., Elliott, M. A., Maiser, S., Karam, C., Caress, J. B., Owegi, M. A., Quick, A., Wymer, J., Goutman, S. A., Heitzman, D., Heiman-Patterson, T., Jackson, C. E., Quinn, C., Rothstein, J. D., Kasarskis, E. J., Katz, J., … Cudkowicz, M. E. (2020). Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis. New England Journal of Medicine, 383(10), 919–930. https://doi.org/10.1056/NEJMoa1916945
[34] Research, C. for D. E. and. (2026). Approved Drug Products with Therapeutic Equivalence Evaluations | Orange Book. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
[35] Essa, S. M., Khosa, N. A., Kakar, A., Öztürk, B., Ibrahim, I. A., & Haq, N. (n.d.). Unraveling the Potential of Stem Cell Therapy in Motor Neuron Disease: A Narrative Review. CNS & Neurological Disorders - Drug Targets, 24, 1–13. https://doi.org/10.2174/0118715273382519250918103218
[36] Oh, K.-W., Noh, M.-Y., Kwon, M.-S., Kim, H. Y., Oh, S.-I., Park, J., Kim, H.-J., Ki, C.-S., & Kim, S. H. (2018). Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis. Annals of Neurology, 84(3), 361–373. https://doi.org/10.1002/ana.25302
[37] Zhang, J., Guo, R., Zhou, Z., Fu, Z., Akogo, H. Y., Li, Y., Zhang, X., Wang, N., Liu, Y., Li, H., Feng, B., Cui, H., & Ma, J. (2025). Neural Stem/Progenitor Cell Therapy in Patients and Animals with Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-analysis. Molecular Neurobiology, 62(5), 6521–6536. https://doi.org/10.1007/s12035-024-04682-8
[38] Lin, C.-F., Chen, Y.-H., Yeh, C.-C., Hsu, S. P. C., & Fu, Y.-S. (2025). Xenotransplantation of Human Umbilical Mesenchymal Stromal Cells Derived from Wharton’s Jelly Mitigates Mouse Amyotrophic Lateral Sclerosis. Stem Cell Research & Therapy, 16(1), 395. https://doi.org/10.1186/s13287-025-04485-1
[39] Hemendinger, R. A., Armstrong, E. J., & Brooks, B. R. (2011). Methyl Vitamin B12 but not methylfolate rescues a motor neuron-like cell line from homocysteine-mediated cell death. Toxicology and Applied Pharmacology, 251(3), 217–225. https://doi.org/10.1016/j.taap.2011.01.003
[40] Rozebalamin(R) for Injection 25 mg (Mecobalamin) Approved in Japan for Amyotrophic Lateral Sclerosis | Nasdaq. (n.d.). Retrieved 22 March 2026, from https://www.nasdaq.com/press-release/rozebalaminr-injection-25-mg-mecobalamin-approved-japan-amyotrophic-lateral-sclerosis
[41] Kaji, R., Izumi, Y., & Oki, R. (2024). Ultra-high dose methylcobalamin and other emerging therapies for amyotrophic lateral sclerosis. Current Opinion in Neurology, 37(5), 593–602. https://doi.org/10.1097/WCO.0000000000001311
[42] Li, Y. N., Gulati, S., Baker, P. J., Brody, L. C., Banerjee, R., & Kruger, W. D. (1996). Cloning, Mapping and RNA Analysis of the Human Methionine Synthase Gene. Human Molecular Genetics, 5(12), 1851–1858. https://doi.org/10.1093/hmg/5.12.1851
[43] ROZEBALAMIN® FOR INJECTION 25 MG (MECOBALAMIN) APPROVED IN JAPAN FOR AMYOTROPHIC LATERAL SCLEROSIS | News ReleaseNews Release：2024. (n.d.). Eisai Co., Ltd. Retrieved 22 March 2026, from https://www.eisai.com/news/2024/news202469.html
[44] Oki, R., Izumi, Y., Fujita, K., Miyamoto, R., Nodera, H., Sato, Y., Sakaguchi, S., Nokihara, H., Kanai, K., Tsunemi, T., Hattori, N., Hatanaka, Y., Sonoo, M., Atsuta, N., Sobue, G., Shimizu, T., Shibuya, K., Ikeda, K., Kano, O., … Japan Early-Stage Trial of Ultrahigh-Dose Methylcobalamin for ALS (JETALS) Collaborators. (2022). Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurology, 79(6), 575–583. https://doi.org/10.1001/jamaneurol.2022.0901
[45] Genge, A., van den Berg, L. H., Frick, G., Han, S., Abikoff, C., Simmons, A., Lin, Q., Patra, K., Kupperman, E., & Berry, J. D. (2023). Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurology, 80(10), 1089–1097. https://doi.org/10.1001/jamaneurol.2023.2851
[46] Ge, T.-Q., Wang, P., & Guan, P.-P. (2026). Targeting the C5-C5aR1 axis: A promising therapeutic strategy for Alzheimer’s disease and amyotrophic lateral sclerosis by unlocking neuroprotection. Biochemical Pharmacology, 243(Pt 1), 117518. https://doi.org/10.1016/j.bcp.2025.117518
[47] Benatar, M., Hansen, T., Rom, D., Geist, M. A., Blaettler, T., Camu, W., Kuzma-Kozakiewicz, M., van den Berg, L. H., Morales, R. J., Chio, A., Andersen, P. M., Pradat, P.-F., Lange, D., Van Damme, P., Mora, G., Grudniak, M., Elliott, M., Petri, S., Olney, N., … ORARIALS-01 trial team. (2024). Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): A randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. The Lancet. Neurology, 23(7), 687–699. https://doi.org/10.1016/S1474-4422(24)00134-0
[48] Benatar, M., Wuu, J., Andersen, P. M., Atassi, N., David, W., Cudkowicz, M., & Schoenfeld, D. (2018). Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology, 90(7), e565–e574. https://doi.org/10.1212/WNL.0000000000004960
[49] Paul, S., & Mahanta, S. (2014). Association of heat-shock proteins in various neurodegenerative disorders: Is it a master key to open the therapeutic door? Molecular and Cellular Biochemistry, 386(1), 45–61. https://doi.org/10.1007/s11010-013-1844-y
[50] Mengel, E., Da Riol, R. M., Del Toro, M., Deodato, F., Gautschi, M., Grunewald, S., Grønborg, S. W., Harmatz, P., Hennermann, J. B., Héron, B., Maier, E. M., Santra, S., Sharma, R., Tylki-Szymanska, A., Cording, M., Himmelstrup, L., Guenther, S., & Dali, C. Í. (2025). Long-term efficacy and safety of arimoclomol in Niemann-Pick disease type C: Final results of the phase 2/3 NPC-002 48-month open-label extension trial. Molecular Genetics and Metabolism, 145(4), 109189. https://doi.org/10.1016/j.ymgme.2025.109189
[51] Gonçalo, A. M. G., & Vieira-Coelho, M. A. (2021). The effects of trazodone on human cognition: A systematic review. European Journal of Clinical Pharmacology, 77(11), 1623–1637. https://doi.org/10.1007/s00228-021-03161-6
[52] Kuns, B., Rosani, A., Patel, P., & Varghese, D. (2026). Memantine. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK500025/
[53] Pal, S., Chataway, J., Swingler, R., Macleod, M. R., Carragher, N. O., Hardingham, G., Selvaraj, B. T., Smith, C., Wong, C., Newton, J., Lyle, D., Stenson, A., Dakin, R. S., Ihenacho, A., Colville, S., Mehta, A. R., Stallard, N., Carpenter, J. R., Parker, R. A., … MND SMART Investigators. (2024). Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): Stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trial. The Lancet. Neurology, 23(11), 1097–1107. https://doi.org/10.1016/S1474-4422(24)00326-0
[54] Bireley, J. D., & Morren, J. A. (2023). CNM-Au8: An experimental agent for the treatment of amyotrophic lateral sclerosis (ALS). Expert Opinion on Investigational Drugs, 32(8), 677–683. https://doi.org/10.1080/13543784.2023.2252738
[55] Writing Committee for the HEALEY ALS Platform Trial & HEALEY ALS Platform Trial Study Group. (2025). CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial. JAMA, 333(13), 1138–1149. https://doi.org/10.1001/jama.2024.27643
[56] Bond, S., Saxena, S., & Sierra-Delgado, J. A. (2025). Microglia in ALS: Insights into Mechanisms and Therapeutic Potential. Cells, 14(6), 421. https://doi.org/10.3390/cells14060421
[57] Hendricus Maes, K. J., & Briedé, J. J. (2026). Repurposing immunomodulatory drugs targeting microglia for amyotrophic lateral sclerosis. Brain Research, 1870, 150032. https://doi.org/10.1016/j.brainres.2025.150032
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Michał Baranowicz, Weronika Mazurkiewicz, Zuzanna Borecka, Agnieszka Marta Sobczak, Alicja Szczot, Anna Jaworowicz, Joanna Piasecka, Bartosz Gołembiewski, Grzegorz Mulski, Martyna Manicka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 122
Number of citations: 0
